SCHEMBL4775014

SCHEMBL4775014

CS(=O)(=O)N(Cc1cc(C(F)(F)F)ccc1Cl)c1ccc(N(C=O)Cc2ccc(C(F)(F)F)nc2)cc1

nearest known ligand 0.38

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 13/20 0.38
KDM4E B2RXH2 2/20 0.37
MAPT P10636 1/20 0.37
HDAC1 Q13547 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
HDAC5 Q9UQL6 1/20 0.36
GAA P10253 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
LMNA P02545 1/20 0.34
HTT P42858 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4767617 0.94 TRPM8 (0.40) TRPM8KDM4EMAPTHDAC1HDAC6
SCHEMBL4777509 0.92 CNR2 (0.37) TRPM8KDM4EMAPTGAAMEN1
SCHEMBL5571164 0.89 GAA (0.44) TRPM8MAPTHDAC6GAAMEN1
SCHEMBL4769701 0.87 CNR2 (0.36) TRPM8KDM4EMAPTGAAMEN1
SCHEMBL5571607 0.86 CNR1 (0.37) TRPM8KDM4EMAPTGAALMNA
SCHEMBL4773550 0.86 HDAC6 (0.44) TRPM8HDAC1HDAC6HDAC5MEN1
SCHEMBL4775075 0.86 CNR2 (0.37) TRPM8KDM4EMAPTMEN1KMT2A
SCHEMBL4770824 0.86 CNR1 (0.35) TRPM8GAALMNA
SCHEMBL4772347 0.85 GAA (0.37) TRPM8HDAC1HDAC6HDAC5GAA
SCHEMBL4772420 0.85 GAA (0.37) TRPM8HDAC1HDAC6HDAC5GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 TRPM8 3499/4885KDM4E 3267/4885MAPT 294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.